MDGL - MADRIGAL PHARMACEUTICALS, INC.

432.83
-6.510   -1.504%

Share volume: 440,075
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$439.34
-6.51
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.64%
1 Month
-11.35%
3 Months
-23.87%
6 Months
-4.62%
1 Year
30.60%
2 Year
72.42%
Key data
Stock price
$432.83
P/E Ratio 
0.00
DAY RANGE
$421.88 - $439.43
EPS 
-$12.85
52 WEEK RANGE
$265.00 - $615.00
52 WEEK CHANGE
$31.50
MARKET CAP 
13.226 B
YIELD 
N/A
SHARES OUTSTANDING 
22.940 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$338,313
AVERAGE 30 VOLUME 
$396,546
Company detail
CEO: Paul A. Friedman
Region: US
Website: madrigalpharma.com
Employees: 90
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.

Recent news